Literature DB >> 11338076

Genotype-phenotype interactions in Wilson's disease: insight from an Icelandic mutation.

R Palsson1, J G Jonasson, M Kristjansson, A Bodvarsson, R D Goldin, D W Cox, S Olafsson.   

Abstract

Wilson's disease, an autosomal recessive disorder of copper transport, usually presents with symptoms from the liver or central nervous system. Rarely, the initial manifestation is fulminant hepatic failure. The abnormal gene (ATP7B) is located on chromosome 13q and encodes a copper-transporting ATPase. A large number of mutations have been reported. We describe a previously healthy 16-year-old girl who presented with fulminant hepatic failure. The girl died within 24 h of admission to a hospital from refractory shock. Autopsy revealed cirrhosis and widespread necrosis of the liver. The copper content of the liver was markedly increased (975 micrograms/g dry weight), strongly suggesting a diagnosis of Wilson's disease. Genetic studies revealed that the girl was homozygous for the mutation 2007 del7, which is the mutation found in all Wilson's disease patients previously identified in Iceland. This is the first known case of fulminant hepatic failure due to Wilson's disease in Iceland. Despite the same mutation, the clinical picture is vastly different from other Icelandic patients with Wilson's disease, who all presented with relatively late-onset neurological disease. This suggests that factors other than the specific mutation have significant impact on the phenotype of the disease.

Entities:  

Mesh:

Year:  2001        PMID: 11338076     DOI: 10.1097/00042737-200104000-00023

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  A new mutation of Wilson's disease P-type ATPase gene in a patient with cirrhosis and coombs-positive hemolytic anemia.

Authors:  Lorenzo Leggio; Giovanni Addolorato; Georgios Loudianos; Ludovico Abenavoli; Maria Barbara Lepori; Fabio Maria Vecchio; Gian Ludovico Rapaccini; Stefano De Virgiliis; Giovanni Gasbarrini
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Homozygosity for Non-H1069Q Missense Mutations in ATP7B Gene and Early Severe Liver Disease: Report of Two Families and a Meta-analysis.

Authors:  Julnar Usta; Hussein Abu Daya; Houssam Halawi; Ibraheem Al-Shareef; Omar El-Rifai; Ahmad H Malli; Ala I Sharara; Robert H Habib; Kassem Barada
Journal:  JIMD Rep       Date:  2011-11-08

3.  Wilson disease: At the crossroads between genetics and epigenetics-A review of the evidence.

Authors:  Dorothy A Kieffer; Valentina Medici
Journal:  Liver Res       Date:  2017-08-16

4.  Analysis of most common mutations R778G, R778L, R778W, I1102T and H1069Q in Indian Wilson disease patients: correlation between genotype/phenotype/copper ATPase activity.

Authors:  Sandeep Kumar; Baburam Thapa; Gurjit Kaur; Rajendra Prasad
Journal:  Mol Cell Biochem       Date:  2006-12-08       Impact factor: 3.396

5.  Correlation of ATP7B genotype with phenotype in Chinese patients with Wilson disease.

Authors:  Xiao-Qing Liu; Ya-Fen Zhang; Tze-Tze Liu; Kwang-Jen Hsiao; Jian-Ming Zhang; Xue-Fan Gu; Ke-Rong Bao; Li-Hua Yu; Mei-Xian Wang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

6.  Analysis of the T1288R mutation of the Wilson disease ATP7B gene in four generations of a family: possible genotype-phenotype correlation with hepatic onset.

Authors:  Lorenzo Leggio; Noemi Malandrino; Georgios Loudianos; Ludovico Abenavoli; Maria Barbara Lepori; Esmeralda Capristo; Stefano De Virgiliis; Giovanni Gasbarrini; Giovanni Addolorato
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

7.  Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease.

Authors:  Uta Merle; Karl Heinz Weiss; Christoph Eisenbach; Sabine Tuma; Peter Ferenci; Wolfgang Stremmel
Journal:  BMC Gastroenterol       Date:  2010-01-18       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.